To conclude, further research is required to determine whether the spatial and temporal pattern of SV2A changes could help to explain PD pathology, distinguish between PD-subtypes and/or atypical Parkinsonism, and could act as a therapeutic biomarker. This evidence concerns the gene SV2A and Parkinsonism.